NCT05518253 is a single-center, double-arm, open-label phase I trial that evaluates the tolerability and safety of CAR-T cells in patients with CD70-expressing advanced/metastatic solid tumors, including renal cell carcinoma and ovarian and cervical cancer [40]. This evidence concerns the gene CD70 and hereditary clear cell renal cell carcinoma.